=Amgen (AMGN) reported earnings on Thur 30 Jan 20 (a/h)

Amgen beats by $0.23, beats on revs; guides FY20 EPS below consensus, revs in-line

Reports Q4 (Dec) earnings of $3.64 per share, $0.23 better than the S&P Capital IQ Consensus of $3.41; revenues fell 0.5% year/year to $6.2 bln vs the $6.04 bln S&P Capital IQ Consensus.

Product sales declined 2% globally, while units grew double digits or better for Repatha (evolocumab), Parsabiv (etelcalcetide), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), Prolia (denosumab), Nplate (romiplostim) and Vectibix (panitumumab).

For the fourth quarter, non-GAAP operating income decreased 4% to $2.6 bln and non-GAAP operating margin decreased 0.7 percentage points to 44.6%.

Co issues guidance for FY20, sees EPS of $14.85-$15.60 vs. $16.10 S&P Capital IQ Consensus; sees FY20 revs of $25.0-$25.6 bln vs. $25.41 bln S&P Capital IQ Consensus.